The role of vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFR) in the angiogenesis and progression of HCC has been well documented [6-8], providing a rationale for investigating VEGF or VEGFR-targeted therapies. The gene discussed is KDR; the disease is hepatocellular carcinoma.